SEARCH

SEARCH BY CITATION

References

  • Agrawal S. K., Theriault E. and Fehlings M. G. (1998) Role of group I metabotropic glutamate receptors in traumatic spinal cord white matter injury. J. Neurotrauma 15, 929941.
  • Alexander G. M., Deitch J. S., Seeburger J. L., Del Valle L. and Heiman-Patterson T. D. (2000) Elevated cortical extracellular fluid glutamate in transgenic mice expressing human mutant (G93A) Cu/Zn superoxide dismutase. J. Neurochem. 74, 16661673.
  • Allan S. M. and Rothwell N. J. (2001) Cytokines and acute neurodegeneration. Nat. Rev. 2, 734744.
  • Allan S. M., Lawrence C. B. and Rothwell N. J. (1998) Interleukin-1 beta and interleukin-1 receptor antagonist do not affect glutamate release or calcium entry in rat striatal synaptosomes. Mol. Psychiatry 3, 178182.
  • Allan S. M., Parker L. C., Collins B., Davies R., Luheshi G. N. and Rothwell N. J. (2000) Cortical cell death induced by IL-1 is mediated via actions in the hypothalamus of the rat. Proc. Natl Acad. Sci. USA 97, 55805585.
  • Allan S. M., Tyrrell P. J. and Rothwell N. J. (2005) Interleukin-1 and neuronal injury. Nat. Rev. 5, 629640.
  • Ances B. M. and Ellis R. J. (2007) Dementia and neurocognitive disorders due to HIV-1 infection. Semin. Neurol. 27, 8692.
  • Andre R., Moggs J. G., Kimber I., Rothwell N. J. and Pinteaux E. (2006) Gene regulation by IL-1beta independent of IL-1R1 in the mouse brain. Glia 53, 477483.
  • Andrei C., Margiocco P., Poggi A., Lotti L. V., Torrisi M. R. and Rubartelli A. (2004) Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: Implications for inflammatory processes. Proc. Natl Acad. Sci. USA 101, 97459750.
  • Angel J., Berenbaum F., Le Denmat C., Nevalainen T., Masliah J. and Fournier C. (1994) Interleukin-1-induced prostaglandin E2 biosynthesis in human synovial cells involves the activation of cytosolic phospholipase A2 and cyclooxygenase-2. Eur. J. Biochem. 226, 125131.
    Direct Link:
  • Aoyama K., Matsumura N., Watabe M. and Nakaki T. (2008) Oxidative stress on EAAC1 is involved in MPTP-induced glutathione depletion and motor dysfunction. Eur. J. Neurosci. 27, 2030.
  • Arzberger T., Krampfl K., Leimgruber S. and Weindl A. (1997) Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington’s disease--an in situ hybridization study. J. Neuropathol. Exp. Neurol. 56, 440454.
  • Auron P. E., Webb A. C., Rosenwasser L. J., Mucci S. F., Rich A., Wolff S. M. and Dinarello C. A. (1984) Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc. Natl Acad. Sci. USA 81, 79077911.
  • Avital A., Goshen I., Kamsler A., Segal M., Iverfeldt K., Richter-Levin G. and Yirmiya R. (2003) Impaired interleukin-1 signaling is associated with deficits in hippocampal memory processes and neural plasticity. Hippocampus 13, 826834.
  • Bagetta G., Corasaniti M. T., Berliocchi L., Nistico R., Giammarioli A. M., Malorni W., Aloe L. and Finazzi-Agro A. (1999) Involvement of interleukin-1beta in the mechanism of human immunodeficiency virus type 1 (HIV-1) recombinant protein gp120-induced apoptosis in the neocortex of rat. Neuroscience 89, 10511066.
  • Balcar V. J. and Li Y. (1992) Heterogeneity of high affinity uptake of L-glutamate and L-aspartate in the mammalian central nervous system. Life Sci. 51, 14671478.
  • Balschun D., Randolf A., Pitossi F., Schneider H., Del Rey A. and Besedovsky H. O. (2003) Hippocampal interleukin-1 beta gene expression during long-term potentiation decays with age. Ann. NY Acad. Sci. 992, 18.
  • Ban E. M., Sarlieve L. L. and Haour F. G. (1993) Interleukin-1 binding sites on astrocytes. Neuroscience 52, 725733.
  • Bannai S. and Tateishi N. (1986) Role of membrane transport in metabolism and function of glutathione in mammals. J. Memb. Biol. 89, 18.
  • Bannon M. J., Goedert M. and Williams B. (1984) The possible relation of glutathione, melanin and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) to Parkinson’s disease. Biochem. Pharmacol. 33, 26972698.
  • Barbour B., Szatkowski M., Ingledew N. and Attwell D. (1989) Arachidonic acid induces a prolonged inhibition of glutamate uptake into glial cells. Nature 342, 918920.
  • Barger S. W. and Basile A. S. (2001) Activation of microglia by secreted amyloid precursor protein evokes release of glutamate by cystine exchange and attenuates synaptic function. J. Neurochem. 76, 846854.
  • Barnham K. J., Masters C. L. and Bush A. I. (2004) Neurodegenerative diseases and oxidative stress. Nat. Rev. 3, 205214.
  • Bartholdi D. and Schwab M. E. (1997) Expression of pro-inflammatory cytokine and chemokine mRNA upon experimental spinal cord injury in mouse: an in situ hybridization study. Eur. J. Neurosci. 9, 14221438.
  • Basu A., Lazovic J., Krady J. K., Mauger D. T., Rothstein R. P., Smith M. B. and Levison S. W. (2005) Interleukin-1 and the interleukin-1 type 1 receptor are essential for the progressive neurodegeneration that ensues subsequent to a mild hypoxic/ischemic injury. J. Cereb. Blood Flow Metab. 25, 1729.
  • Bazan J. F., Timans J. C. and Kastelein R. A. (1996) A newly defined interleukin-1? Nature 379, 591.
  • Beal M. F. (1992) Role of excitotoxicity in human neurological disease. Curr. Opin. Neurobiol. 2, 657662.
  • Beal M. F. (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38, 357366.
  • Beal M. F. (1998) Excitotoxicity and nitric oxide in Parkinson’s disease pathogenesis. Ann. Neurol. 44, S110S114.
  • Beal M. F., Brouillet E., Jenkins B., Henshaw R., Rosen B. and Hyman B. T. (1993) Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J. Neurochem. 61, 11471150.
  • Behl C. and Moosmann B. (2002) Oxidative nerve cell death in Alzheimer’s disease and stroke: antioxidants as neuroprotective compounds. Biol. Chem. 383, 521536.
  • Behrens P. F., Franz P., Woodman B., Lindenberg K. S. and Landwehrmeyer G. B. (2002) Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 125, 19081922.
  • Bendotti C. and Carri M. T. (2004) Lessons from models of SOD1-linked familial ALS. Trends in molecular medicine 10, 393400.
  • Benveniste H. (1991) The excitotoxin hypothesis in relation to cerebral ischemia. Cerebrovasc. Brain Metab. Rev. 3, 213245.
  • Benveniste E. N., Sparacio S. M., Norris J. G., Grenett H. E. and Fuller G. M. (1990) Induction and regulation of interleukin-6 gene expression in rat astrocytes. J. Neuroimmunol. 30, 201212.
  • Bernardino L., Xapelli S., Silva A. P., Jakobsen B., Poulsen F. R., Oliveira C. R., Vezzani A., Malva J. O. and Zimmer J. (2005) Modulator effects of interleukin-1beta and tumor necrosis factor-alpha on AMPA-induced excitotoxicity in mouse organotypic hippocampal slice cultures. J. Neurosci. 25, 67346744.
  • Betz A. L., Yang G. Y. and Davidson B. L. (1995) Attenuation of stroke size in rats using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist in brain. J. Cereb. Blood Flow Metab. 15, 547551.
  • Betz A. L., Schielke G. P. and Yang G. Y. (1996) Interleukin-1 in cerebral ischemia. Keio J. Med. 45, 230237; discussion 238.
  • Bianco F., Pravettoni E., Colombo A., Schenk U., Moller T., Matteoli M. and Verderio C. (2005) Astrocyte-derived ATP induces vesicle shedding and IL-1 beta release from microglia. J. Immunol. 174, 72687277.
  • Blasi F., Riccio M., Brogi A. et al. (1999) Constitutive expression of interleukin-1beta (IL-1beta) in rat oligodendrocytes. Biol. Chem. 380, 259264.
  • Bliss T. V. and Collingridge G. L. (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361, 3139.
  • Bogdanov M. B., Andreassen O. A., Dedeoglu A., Ferrante R. J. and Beal M. F. (2001) Increased oxidative damage to DNA in a transgenic mouse model of Huntington’s disease. J. Neurochem. 79, 12461249.
  • Boutin H., LeFeuvre R. A., Horai R., Asano M., Iwakura Y. and Rothwell N. J. (2001) Role of IL-1alpha and IL-1beta in ischemic brain damage. J. Neurosci. 21, 55285534.
  • Brabers N. A. and Nottet H. S. (2006) Role of the pro-inflammatory cytokines TNF-alpha and IL-1beta in HIV-associated dementia. Eur. J. Clin. Invest. 36, 447458.
  • Breder C. D., Dinarello C. A. and Saper C. B. (1988) Interleukin-1 immunoreactive innervation of the human hypothalamus. Science (New York, NY) 240, 321324.
  • Brough D. and Rothwell N. J. (2007) Caspase-1-dependent processing of pro-interleukin-1beta is cytosolic and precedes cell death. J. Cell Sci. 120, 772781.
  • Brown D. R. (1999) Neurons depend on astrocytes in a coculture system for protection from glutamate toxicity. Mol. Cell. Neurosci. 13, 379389.
  • Browne S. E. and Beal M. F. (2006) Oxidative damage in Huntington’s disease pathogenesis. Antioxid. Redox Signal. 8, 20612073.
  • Butterfield D. A., Howard B. J. and LaFontaine M. A. (2001) Brain oxidative stress in animal models of accelerated aging and the age-related neurodegenerative disorders, Alzheimer’s disease and Huntington’s disease. Current medicinal chemistry 8, 815828.
  • Buttini M., Sauter A. and Boddeke H. W. (1994) Induction of interleukin-1 beta mRNA after focal cerebral ischaemia in the rat. Brain Res. 23, 126134.
  • Cacabelos R., Barquero M., Garcia P., Alvarez X. A. and Varela de Seijas E. (1991) Cerebrospinal fluid interleukin-1 beta (IL-1 beta) in Alzheimer’s disease and neurological disorders. Methods Find. Exp. Clin. Pharmacol. 13, 455458.
  • Carlson N. G., Wieggel W. A., Chen J., Bacchi A., Rogers S. W. and Gahring L. C. (1999) Inflammatory cytokines IL-1 alpha, IL-1 beta, IL-6, and TNF-alpha impart neuroprotection to an excitotoxin through distinct pathways. J. Immunol. 163, 39633968.
  • Carmeliet P., Van Damme J. and Denef C. (1989) Interleukin-1 beta inhibits acetylcholine synthesis in the pituitary corticotropic cell line AtT20. Brain Res. 491, 199203.
  • Castillo J., Davalos A. and Noya M. (1999) Aggravation of acute ischemic stroke by hyperthermia is related to an excitotoxic mechanism. Cerebrovasc. Dis. (Basel, Switzerland) 9, 2227.
  • Cepeda C., Ariano M. A., Calvert C. R., Flores-Hernandez J., Chandler S. H., Leavitt B. R., Hayden M. R. and Levine M. S. (2001) NMDA receptor function in mouse models of Huntington disease. J. Neurosci. Res. 66, 525539.
  • Cerretti D. P., Kozlosky C. J., Mosley B. et al. (1992) Molecular cloning of the interleukin-1 beta converting enzyme. Science (New York, NY) 256, 97100.
  • Chao M. V., Rajagopal R. and Lee F. S. (2006) Neurotrophin signalling in health and disease. Clin. Sci. (Lond) 110, 167173.
  • Ching S., Zhang H., Belevych N., He L., Lai W., Pu X. A., Jaeger L. B., Chen Q. and Quan N. (2007) Endothelial-specific knockdown of interleukin-1 (IL-1) type 1 receptor differentially alters CNS responses to IL-1 depending on its route of administration. J. Neurosci. 27, 1047610486.
  • Chinta S. J., Kumar M. J., Hsu M., Rajagopalan S., Kaur D., Rane A., Nicholls D. G., Choi J. and Andersen J. K. (2007) Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration. J. Neurosci. 27, 1399714006.
  • Choi D. W. (1988) Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends Neurosci. 11, 465469.
  • Chopp M., Welch K. M., Tidwell C. D., Knight R. and Helpern J. A. (1988) Effect of mild hyperthermia on recovery of metabolic function after global cerebral ischemia in cats. Stroke; J. Cerebral Circ. 19, 15211525.
  • Colotta F., Re F., Muzio M., Bertini R., Polentarutti N., Sironi M., Giri J. G., Dower S. K., Sims J. E. and Mantovani A. (1993) Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science (New York, NY) 261, 472475.
  • Conti A., Miscusi M., Cardali S., Germano A., Suzuki H., Cuzzocrea S. and Tomasello F. (2007) Nitric oxide in the injured spinal cord: synthases cross-talk, oxidative stress and inflammation. Brain Res. Rev. 54, 205218.
  • Cookson M. R., Menzies F. M., Manning P., Eggett C. J., Figlewicz D. A., McNeil C. J. and Shaw P. J. (2002) Cu/Zn superoxide dismutase (SOD1) mutations associated with familial amyotrophic lateral sclerosis (ALS) affect cellular free radical release in the presence of oxidative stress. Amyotroph Lateral Scler. Motor Neuron Disord. 3, 7585.
  • Coyle J. T. and Puttfarcken P. (1993) Oxidative stress, glutamate, and neurodegenerative disorders. Science (New York, NY) 262, 689695.
  • Cross A. H., Manning P. T., Keeling R. M., Schmidt R. E. and Misko T. P. (1998) Peroxynitrite formation within the central nervous system in active multiple sclerosis. J. Neuroimmunol. 88, 4556.
  • Cuajungco M. P., Goldstein L. E., Nunomura A., Smith M. A., Lim J. T., Atwood C. S., Huang X., Farrag Y. W., Perry G. and Bush A. I. (2000) Evidence that the beta-amyloid plaques of Alzheimer’s disease represent the redox-silencing and entombment of abeta by zinc. J. Biol. Chem. 275, 1943919442.
  • Da Cunha A., Jefferson J. A., Jackson R. W. and Vitkovic L. (1993) Glial cell-specific mechanisms of TGF-beta 1 induction by IL-1 in cerebral cortex. J. Neuroimmunol. 42, 7185.
  • Cunningham Jr E. T. and De Souza E. B. (1993) Interleukin 1 receptors in the brain and endocrine tissues. Immunol. Today 14, 171176.
  • Curtis B. M., Widmer M. B., DeRoos P. and Qwarnstrom E. E. (1990) IL-1 and its receptor are translocated to the nucleus. J. Immunol. 144, 12951303.
  • Danbolt N. C. (2001) Glutamate uptake. Prog. Neurobiol. 65, 1105.
  • Davies C. A., Loddick S. A., Toulmond S., Stroemer R. P., Hunt J. and Rothwell N. J. (1999) The progression and topographic distribution of interleukin-1beta expression after permanent middle cerebral artery occlusion in the rat. J. Cereb. Blood Flow Metab. 19, 8798.
  • Dayton E. T. and Major E. O. (1996) Recombinant human interleukin 1 beta induces production of prostaglandins in primary human fetal astrocytes and immortalized human fetal astrocyte cultures. J. Neuroimmunol. 71, 1118.
  • Debets R., Timans J. C., Homey B. et al. (2001) Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2. J. Immunol. 167, 14401446.
  • Deneke S. M. and Fanburg B. L. (1989) Regulation of cellular glutathione. Am. J. Physiol. 257, L163L173.
  • Dervan A. G., Meshul C. K., Beales M., McBean G. J., Moore C., Totterdell S., Snyder A. K. and Meredith G. E. (2004) Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson’s disease. Exp. Neurol. 190, 145156.
  • Desson S. E. and Ferguson A. V. (2003) Interleukin 1beta modulates rat subfornical organ neurons as a result of activation of a non-selective cationic conductance. J. Physiol. 550, 113122.
  • Diab A., Zhu J., Xiao B. G., Mustafa M. and Link H. (1997) High IL-6 and low IL-10 in the central nervous system are associated with protracted relapsing EAE in DA rats. J. Neuropathol. Exp. Neurol. 56, 641650.
  • Diana A., Van Dam A. M., Winblad B. and Schultzberg M. (1999) Co-localization of interleukin-1 receptor type I and interleukin-1 receptor antagonist with vasopressin in magnocellular neurons of the paraventricular and supraoptic nuclei of the rat hypothalamus. Neuroscience 89, 137147.
  • Diem R., Hobom M., Grotsch P., Kramer B. and Bahr M. (2003) Interleukin-1 beta protects neurons via the interleukin-1 (IL-1) receptor-mediated Akt pathway and by IL-1 receptor-independent decrease of transmembrane currents in vivo. Mol. Cell. Neurosci. 22, 487500.
  • Dietrich W. D., Busto R., Globus M. Y. and Ginsberg M. D. (1996) Brain damage and temperature: cellular and molecular mechanisms. Adv. Neurol. 71, 177194.
  • Dinarello C. A. (1994) The interleukin-1 family: 10 years of discovery. FASEB J. 8, 13141325.
  • Dinarello C. A. (1996) Biologic basis for interleukin-1 in disease. Blood 87, 20952147.
  • Dinarello C. A. (1998) Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int. Rev. Immunol. 16, 457499.
  • Dinarello C. A. (2002) The IL-1 family and inflammatory diseases. Clin. Exp. Rheumatol. 20, S1S13.
  • Dinarello C. A. and Thompson R. C. (1991) Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol. Today 12, 404410.
  • Dinarello C. A. and Wolff S. M. (1993) The role of interleukin-1 in disease. N. Engl. J. Med. 328, 106113.
  • Domercq M., Sanchez-Gomez M. V., Sherwin C., Etxebarria E., Fern R. and Matute C. (2007) System xc- and glutamate transporter inhibition mediates microglial toxicity to oligodendrocytes. J. Immunol. 178, 65496556.
  • Drejer J., Benveniste H., Diemer N. H. and Schousboe A. (1985) Cellular origin of ischemia-induced glutamate release from brain tissue in vivo and in vitro. J. Neurochem. 45, 145151.
  • Dringen R. (2000) Glutathione metabolism and oxidative stress in neurodegeneration. Eur. J. Biochem. 267, 4903.
  • Dripps D. J., Brandhuber B. J., Thompson R. C. and Eisenberg S. P. (1991) Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J. Biol. Chem. 266, 1033110336.
  • Dugan L. L., Sensi S. L., Canzoniero L. M., Handran S. D., Rothman S. M., Lin T. S., Goldberg M. P. and Choi D. W. (1995) Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate. J. Neurosci. 15, 63776388.
  • Dun Y., Mysona B., Van Ells T., Amarnath L., Ola M. S., Ganapathy V. and Smith S. B. (2006) Expression of the cystine-glutamate exchanger (xc-) in retinal ganglion cells and regulation by nitric oxide and oxidative stress. Cell Tissue Res. 324, 189202.
  • Dunn E., Sims J. E., Nicklin M. J. and O’Neill L. A. (2001) Annotating genes with potential roles in the immune system: six new members of the IL-1 family. Trends Immunol. 22, 533536.
  • Dunnett S. B. and Rosser A. E. (2004) Cell therapy in Huntington’s disease. NeuroRx 1, 394405.
  • Emerit J., Edeas M. and Bricaire F. (2004) Neurodegenerative diseases and oxidative stress. Biomed. Pharmacother. Biomed. Pharmacother. 58, 3946.
  • Emsley H. C., Smith C. J., Georgiou R. F., Vail A., Hopkins S. J., Rothwell N. J. and Tyrrell P. J. (2005) A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J. Neurol. Neurosurg. Psychiatry 76, 13661372.
  • Endres S., Cannon J. G., Ghorbani R., Dempsey R. A., Sisson S. D., Lonnemann G., Van der Meer J. W., Wolff S. M. and Dinarello C. A. (1989) In vitro production of IL 1 beta, IL 1 alpha, TNF and IL2 in healthy subjects: distribution, effect of cyclooxygenase inhibition and evidence of independent gene regulation. Eur. J. Immunol. 19, 23272333.
  • Faden A. I. (1993) Experimental neurobiology of central nervous system trauma. Crit. Rev. Neurobiol. 7, 175186.
  • Faden A. I. and Salzman S. (1992) Pharmacological strategies in CNS trauma. Trends Pharmacol. Sci. 13, 2935.
  • Faden A. I., O’Leary D. M., Fan L., Bao W., Mullins P. G. and Movsesyan V. A. (2001) Selective blockade of the mGluR1 receptor reduces traumatic neuronal injury in vitro and improvesoOutcome after brain trauma. Exp. Neurol. 167, 435444.
  • Fan M. M. Y. and Raymond L. A. (2007) N-Methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington’s disease. Prog. Neurobiol. 81, 272293.
  • Fan L., Young P. R., Barone F. C., Feuerstein G. Z., Smith D. H. and McIntosh T. K. (1995) Experimental brain injury induces expression of interleukin-1 beta mRNA in the rat brain. Brain Res. 30, 125130.
  • Fang J., Wang Y. and Krueger J. M. (1998) Effects of interleukin-1 beta on sleep are mediated by the type I receptor. Am. J. Physiol. 274, R655R660.
  • Farrar W. L., Kilian P. L., Ruff M. R., Hill J. M. and Pert C. B. (1987) Visualization and characterization of interleukin 1 receptors in brain. J. Immunol. 139, 459463.
  • Felderhoff-Mueser U., Schmidt O. I., Oberholzer A., Buhrer C. and Stahel P. F. (2005) IL-18: a key player in neuroinflammation and neurodegeneration? Trends Neurosci. 28, 487493.
  • Ferraguti F., Pietra C., Valerio E., Corti C., Chiamulera C. and Conquet F. (1997) Evidence against a permissive role of the metabotropic glutamate receptor 1 in acute excitotoxicity. Neuroscience 79, 15.
  • Ferrari D., Chiozzi P., Falzoni S., Dal Susino M., Melchiorri L., Baricordi O. R. and Di Virgilio F. (1997) Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages. J. Immunol. 159, 14511458.
  • Ferrari C. C., Pott Godoy M. C., Tarelli R., Chertoff M., Depino A. M. and Pitossi F. J. (2006) Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra. Neurobiol. Dis. 24, 183193.
  • Fink S. L., Ho D. Y. and Sapolsky R. M. (1996) Energy and glutamate dependency of 3-Nitropropionic acid neurotoxicity in culture. Exp. Neurol. 138, 298304.
  • Fogal B., Li J., Lobner D., McCullough L. D. and Hewett S. J. (2007) System x(c)- activity and astrocytes are necessary for interleukin-1 beta-mediated hypoxic neuronal injury. J. Neurosci. 27, 1009410105.
  • Fonnum F. (1984) Glutamate: a neurotransmitter in mammalian brain. J. Neurochem. 42, 111.
  • Fox J. H., Barber D. S., Singh B. et al. (2004) Cystamine increases L-cysteine levels in Huntington’s disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. J. Neurochem. 91, 413422.
  • Fray A. E., Ince P. G., Banner S. J., Milton I. D., Usher P. A., Cookson M. R. and Shaw P. J. (1998) The expression of the glial glutamate transporter protein EAAT2 in motor neuron disease: an immunohistochemical study. Eur. J. Neuroscience 10, 24812489.
  • French R. A., VanHoy R. W., Chizzonite R., Zachary J. F., Dantzer R., Parnet P., Bluthe R. M. and Kelley K. W. (1999) Expression and localization of p80 and p68 interleukin-1 receptor proteins in the brain of adult mice. J. Neuroimmunol. 93, 194202.
  • Friedlander R. M., Brown R. H., Gagliardini V., Wang J. and Yuan J. (1997a) Inhibition of ICE slows ALS in mice. Nature 388, 31.
  • Friedlander R. M., Gagliardini V., Hara H., Fink K. B., Li W., MacDonald G., Fishman M. C., Greenberg A. H., Moskowitz M. A. and Yuan J. (1997b) Expression of a dominant negative mutant of interleukin-1 beta converting enzyme in transgenic mice prevents neuronal cell death induced by trophic factor withdrawal and ischemic brain injury. J. Exp. Med. 185, 933940.
  • Friedman W. J. (2001) Cytokines regulate expression of the type 1 interleukin-1 receptor in rat hippocampal neurons and glia. Exp. Neurol. 168, 2331.
  • Garcia J. H., Liu K. F. and Relton J. K. (1995) Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats with middle cerebral artery occlusion. Am. J. Pathol. 147, 14771486.
  • Gayle M. A., Sims J. E., Dower S. K. and Slack J. L. (1994) Monoclonal antibody 1994-01 (also known as ALVA 42) reported to recognize type II IL-1 receptor is specific for HLA-DR alpha and beta chains. Cytokine 6, 8386.
  • Giacobini E. (2003) Cholinesterases: new roles in brain function and in Alzheimer’s disease. Neurochem. Res. 28, 515522.
  • Ginsberg M. D. and Busto R. (1998) Combating hyperthermia in acute stroke: a significant clinical concern. Stroke; J. Cerebral Circ. 29, 529534.
  • Giri J. G., Lomedico P. T. and Mizel S. B. (1985) Studies on the synthesis and secretion of interleukin 1. I. A 33,000 molecular weight precursor for interleukin 1. J. Immunol. 134, 343349.
  • Giulian D., Baker T. J., Shih L. C. and Lachman L. B. (1986) Interleukin 1 of the central nervous system is produced by ameboid microglia. J. Exp. Med. 164, 594604.
  • Glaccum M. B., Stocking K. L., Charrier K., Smith J. L., Willis C. R., Maliszewski C., Livingston D. J., Peschon J. J. and Morrissey P. J. (1997) Phenotypic and functional characterization of mice that lack the type I receptor for IL-1. J. Immunol. 159, 33643371.
  • Goldgaber D., Harris H. W., Hla T., Maciag T., Donnelly R. J., Jacobsen J. S., Vitek M. P. and Gajdusek D. C. (1989) Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc. Natl Acad. Sci. USA 86, 76067610.
  • Gonsette R. E. (2008) Review: oxidative stress and excitotoxicity: a therapeutic issue in multiple sclerosis? Multiple sclerosis (Houndmills, Basingstoke, England) 14, 2234.
  • Good P. F., Werner P., Hsu A., Olanow C. W. and Perl D. P. (1996) Evidence of neuronal oxidative damage in Alzheimer’s disease. Am. J. Pathol. 149, 2128.
  • Gracie J. A., Robertson S. E. and McInnes I. B. (2003) Interleukin-18. J. Leukoc. Biol. 73, 213224.
  • Gray P. W., Glaister D., Chen E., Goeddel D. V. and Pennica D. (1986) Two interleukin 1 genes in the mouse: cloning and expression of the cDNA for murine interleukin 1 beta. J. Immunol. 137, 36443648.
  • Grenfell S., Smithers N., Miller K. and Solari R. (1989) Receptor-mediated endocytosis and nuclear transport of human interleukin 1 alpha. Biochem. J. 264, 813822.
  • Griffin W. S., Stanley L. C., Ling C., White L., MacLeod V., Perrot L. J., White III C. L. and Araoz C. (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl Acad. Sci. USA 86, 76117615.
  • Griffin W. S., Liu L., Li Y., Mrak R. E. and Barger S. W. (2006) Interleukin-1 mediates Alzheimer and Lewy body pathologies. J. Neuroinflamm. 3, 5.
  • Griffiths R. J., Stam E. J., Downs J. T. and Otterness I. G. (1995) ATP induces the release of IL-1 from LPS-primed cells in vivo. J. Immunol. 154, 28212828.
  • Grimaldi L. M., Casadei V. M., Ferri C. et al. (2000) Association of early-onset Alzheimer’s disease with an interleukin-1alpha gene polymorphism. Ann. Neurol. 47, 361365.
  • Gurney M. E., Pu H., Chiu A. Y. et al. (1994) Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science (New York, NY) 264, 17721775.
  • Gusev E. and Skvortsova V. I. (2003) Dynamics of pro-inflammatory and regulatory cytokines and C-reactive protein concentration in CSF of patients with acute ischemic stroke, in Brain Ischemia (GusevE., ed.), pp. 125135. Kluwer Academic/Plenum Publishers, New York.
  • Hall E. D., Andrus P. K. and Yonkers P. A. (1993) Brain hydroxyl radical generation in acute experimental head injury. J. Neurochem. 60, 588594.
  • Hamann M., Rossi D. J., Marie H. and Attwell D. (2002) Knocking out the glial glutamate transporter GLT-1 reduces glutamate uptake but does not affect hippocampal glutamate dynamics in early simulated ischaemia. Eur. J. Neurosci. 15, 308314.
  • Hammond E. A., Smart D., Toulmond S., Suman-Chauhan N., Hughes J. and Hall M. D. (1999) The interleukin-1 type I receptor is expressed in human hypothalamus. Brain 122, 16971707.
  • Hao J. X., Watson B. D., Xu X. J., Wiesenfeld-Hallin Z., Seiger A. and Sundstrom E. (1992) Protective effect of the NMDA antagonist MK-801 on photochemically induced spinal lesions in the rat. Exp. Neurol. 118, 143152.
  • Hara H., Fink K., Endres M., Friedlander R. M., Gagliardini V., Yuan J. and Moskowitz M. A. (1997) Attenuation of transient focal cerebral ischemic injury in transgenic mice expressing a mutant ICE inhibitory protein. J. Cereb. Blood Flow Metab. 17, 370375.
  • Hartung H. P., Schafer B., Heininger K. and Toyka K. V. (1989) Recombinant interleukin-1 beta stimulates eicosanoid production in rat primary culture astrocytes. Brain Res. 489, 113119.
  • Hazell A. S. (2007) Excitotoxic mechanisms in stroke: an update of concepts and treatment strategies. Neurochem. Int. 50, 941953.
  • Heath P. R. and Shaw P. J. (2002) Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve 26, 438458.
  • Hermans G., Stinissen P., Hauben L., Van den Berg-Loonen E., Raus J. and Zhang J. (1997) Cytokine profile of myelin basic protein-reactive T cells in multiple sclerosis and healthy individuals. Ann. Neurol. 42, 1827.
  • Herx L. M., Rivest S. and Yong V. W. (2000) Central nervous system-initiated inflammation and neurotrophism in trauma: IL-1 beta is required for the production of ciliary neurotrophic factor. J. Immunol. 165, 22322239.
  • Hetier E., Ayala J., Denefle P., Bousseau A., Rouget P., Mallat M. and Prochiantz A. (1988) Brain macrophages synthesize interleukin-1 and interleukin-1 mRNAs in vitro. J. Neurosci. Res. 21, 391397.
  • Hewett S. J., Corbett J. A., McDaniel M. L. and Choi D. W. (1993) Interferon-gamma and interleukin-1 beta induce nitric oxide formation from primary mouse astrocytes. Neurosci. Lett. 164, 229232.
  • Hewett S. J., Muir J. K., Lobner D., Symons A. and Choi D. W. (1996) Potentiation of oxygen-glucose deprivation-induced neuronal death after induction of iNOS. Stroke; J. Cerebral Circ. 27, 15861591.
  • Hogquist K. A., Unanue E. R. and Chaplin D. D. (1991) Release of IL-1 from mononuclear phagocytes. J. Immunol. 147, 21812186.
  • Holmer H. K., Keyghobadi M., Moore C. and Meshul C. K. (2005) l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 136, 333341.
  • Holmin S. and Hojeberg B. (2004) In situ detection of intracerebral cytokine expression after human brain contusion. Neurosci. Lett. 369, 108114.
  • Horai R., Asano M., Sudo K., Kanuka H., Suzuki M., Nishihara M., Takahashi M. and Iwakura Y. (1998) Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J. Exp. Med. 187, 14631475.
  • Hu S., Sheng W. S., Ehrlich L. C., Peterson P. K. and Chao C. C. (2000) Cytokine effects on glutamate uptake by human astrocytes. Neuroimmunomodulation 7, 153159.
  • Huitinga I., Van Der Cammen M., Salm L., Erkut Z., Van Dam A., Tilders F. and Swaab D. (2000) IL-1beta immunoreactive neurons in the human hypothalamus: reduced numbers in multiple sclerosis. J. Neuroimmunol. 107, 820.
  • Ilyin S. E., Gayle D., Flynn M. C. and Plata-Salaman C. R. (1998) Interleukin-1beta system (ligand, receptor type I, receptor accessory protein and receptor antagonist), TNF-alpha, TGF-beta1 and neuropeptide Y mRNAs in specific brain regions during bacterial LPS-induced anorexia. Brain Res. Bull. 45, 507515.
  • Jabaudon D., Shimamoto K., Yasuda-Kamatani Y., Scanziani M., Gahwiler B. H. and Gerber U. (1999) Inhibition of uptake unmasks rapid extracellular turnover of glutamate of nonvesicular origin. Proc. Natl Acad. Sci. USA 96, 87338738.
  • Jabaudon D., Scanziani M., Gahwiler B. H. and Gerber U. (2000) Acute decrease in net glutamate uptake during energy deprivation. Proc. Natl Acad. Sci. USA 97, 56105615.
  • Jander S., Schroeter M. and Stoll G. (2000) Role of NMDA receptor signaling in the regulation of inflammatory gene expression after focal brain ischemia. J. Neuroimmunol. 109, 181187.
  • Jander S., Schroeter M., Peters O., Witte O. W. and Stoll G. (2001) Cortical spreading depression induces proinflammatory cytokine gene expression in the rat brain. J. Cereb. Blood Flow Metab. 21, 218225.
  • Jenner P. and Olanow C. W. (2006) The pathogenesis of cell death in Parkinson’s disease. Neurology 66, S24S36.
  • Johannessen J. N., Chiueh C. C., Burns R. S. and Markey S. P. (1985) Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects. Life Sci. 36, 219224.
  • Jones N. C., Prior M. J., Burden-Teh E., Marsden C. A., Morris P. G. and Murphy S. (2005) Antagonism of the interleukin-1 receptor following traumatic brain injury in the mouse reduces the number of nitric oxide synthase-2-positive cells and improves anatomical and functional outcomes. Eur. J. Neurosci. 22, 7278.
  • Juric D. M. and Carman-Krzan M. (2001) Interleukin-1 beta, but not IL-1 alpha, mediates nerve growth factor secretion from rat astrocytes via type I IL-1 receptor. Int. J. Dev. Neurosci. 19, 675683.
  • Kamm K., Vanderkolk W., Lawrence C., Jonker M. and Davis A. T. (2006) The effect of traumatic brain injury upon the concentration and expression of interleukin-1beta and interleukin-10 in the rat. J. Trauma 60, 152157.
  • Kapsimalis F., Richardson G., Opp M. R. and Kryger M. (2005) Cytokines and normal sleep. Curr. Opin. Pulmonary Med. 11, 481484.
  • Kasahara T., Mukaida N., Yamashita K., Yagisawa H., Akahoshi T. and Matsushima K. (1991) IL-1 and TNF-alpha induction of IL-8 and monocyte chemotactic and activating factor (MCAF) mRNA expression in a human astrocytoma cell line. Immunology 74, 6067.
  • Katabami T., Shimizu M., Okano K. et al. (1992) Intracellular signal transduction for interleukin-1 beta-induced endothelin production in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 188, 565570.
  • Katayama Y., Becker D. P., Tamura T. and Hovda D. A. (1990) Massive increases in extracellular potassium and the indiscriminate release of glutamate following concussive brain injury. J. Neurosurg. 73, 889900.
  • Katayama Y., Kawamata T., Tamura T., Hovda D. A., Becker D. P. and Tsubokawa T. (1991) Calcium-dependent glutamate release concomitant with massive potassium flux during cerebral ischemia in vivo. Brain Res. 558, 136140.
  • Kaul M., Garden G. A. and Lipton S. A. (2001) Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410, 988994.
  • Kawaguchi Y., Nishimagi E., Tochimoto A., Kawamoto M., Katsumata Y., Soejima M., Kanno T., Kamatani N. and Hara M. (2006) Intracellular IL-1{alpha}-binding proteins contribute to biological functions of endogenous IL-1{alpha} in systemic sclerosis fibroblasts. Proc. Natl Acad. Sci. 103, 1450114506.
  • Kim G. W., Copin J. C., Kawase M., Chen S. F., Sato S., Gobbel G. T. and Chan P. H. (2000) Excitotoxicity is required for induction of oxidative stress and apoptosis in mouse striatum by the mitochondrial toxin, 3-nitropropionic acid. J. Cereb. Blood Flow Metab. 20, 119129.
  • Kimelberg H. K., Goderie S. K., Higman S., Pang S. and Waniewski R. A. (1990) Swelling-induced release of glutamate, aspartate, and taurine from astrocyte cultures. J. Neurosci. 10, 15831591.
  • Kimelberg H. K., Nestor N. B. and Feustel P. J. (2004) Inhibition of release of taurine and excitatory amino acids in ischemia and neuroprotection. Neurochem. Res. 29, 267274.
  • Kinoshita K., Chatzipanteli K., Vitarbo E., Truettner J. S., Alonso O. F. and Dietrich W. D. (2002) Interleukin-1beta messenger ribonucleic acid and protein levels after fluid-percussion brain injury in rats: importance of injury severity and brain temperature. Neurosurgery 51, 195203.
  • Klevenyi P., Andreassen O., Ferrante R. J., Schleicher Jr J. R., Friedlander R. M. and Beal M. F. (1999) Transgenic mice expressing a dominant negative mutant interleukin-1beta converting enzyme show resistance to MPTP neurotoxicity. Neuroreport 10, 635638.
  • Knerlich F., Schilling L., Gorlach C., Wahl M., Ehrenreich H. and Siren A. L. (1999) Temporal profile of expression and cellular localization of inducible nitric oxide synthase, interleukin-1beta and interleukin converting enzyme after cryogenic lesion of the rat parietal cortex. Brain Res. 68, 7387.
  • Konsman J. P., Vigues S., Mackerlova L., Bristow A. and Blomqvist A. (2004) Rat brain vascular distribution of interleukin-1 type-1 receptor immunoreactivity: relationship to patterns of inducible cyclooxygenase expression by peripheral inflammatory stimuli. J. Comp. Neurol. 472, 113129.
  • Krueger J. M., Fang J., Taishi P., Chen Z., Kushikata T. and Gardi J. (1998) Sleep. A physiologic role for IL-1 beta and TNF-alpha. Ann. NY Acad. Sci. 856, 148159.
  • Krueger J. M., Obal F. J., Fang J., Kubota T. and Taishi P. (2001) The role of cytokines in physiological sleep regulation. Ann. NY Acad. Sci. 933, 211221.
  • Lafage M., Maroc N., Dubreuil P., De Waal Malefijt R., Pebusque M. J., Carcassonne Y. and Mannoni P. (1989) The human interleukin-1 alpha gene is located on the long arm of chromosome 2 at band q13. Blood 73, 104107.
  • Lafon-Cazal M., Pietri S., Culcasi M. and Bockaert J. (1993a) NMDA-dependent superoxide production and neurotoxicity. Nature 364, 535537.
  • Lafon-Cazal M., Culcasi M., Gaven F., Pietri S. and Bockaert J. (1993b) Nitric oxide, superoxide and peroxynitrite: putative mediators of NMDA-induced cell death in cerebellar granule cells. Neuropharmacology 32, 12591266.
  • Laliberte R. E., Perregaux D. G., Hoth L. R., Rosner P. J., Jordan C. K., Peese K. M., Eggler J. F., Dombroski M. A., Geoghegan K. F. and Gabel C. A. (2003) Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing. J. Biol. Chem. 278, 1656716578.
  • Lawrence C. B., Allan S. M. and Rothwell N. J. (1998) Interleukin-1beta and the interleukin-1 receptor antagonist act in the striatum to modify excitotoxic brain damage in the rat. Eur. J. Neurosci. 10, 11881195.
  • Lazovic J., Basu A., Lin H. W., Rothstein R. P., Krady J. K., Smith M. B. and Levison S. W. (2005) Neuroinflammation and both cytotoxic and vasogenic edema are reduced in interleukin-1 type 1 receptor-deficient mice conferring neuroprotection. Stroke; J. Cerebral Circ. 36, 22262231.
  • Le Feuvre R., Brough D. and Rothwell N. (2002a) Extracellular ATP and P2X7 receptors in neurodegeneration. Eur. J. Pharmacol. 447, 261269.
  • Le Feuvre R. A., Brough D., Iwakura Y., Takeda K. and Rothwell N. J. (2002b) Priming of macrophages with lipopolysaccharide potentiates P2X7-mediated cell death via a caspase-1-dependent mechanism, independently of cytokine production. J. Biol. Chem. 277, 32103218.
  • Lechan R. M., Toni R., Clark B. D., Cannon J. G., Shaw A. R., Dinarello C. A. and Reichlin S. (1990) Immunoreactive interleukin-1 beta localization in the rat forebrain. Brain Res. 514, 135140.
  • Lee S. C., Dickson D. W., Liu W. and Brosnan C. F. (1993) Induction of nitric oxide synthase activity in human astrocytes by interleukin-1 beta and interferon-gamma. J. Neuroimmunol. 46, 1924.
  • Lee H. G., Casadesus G., Zhu X., Takeda A., Perry G. and Smith M. A. (2004) Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann. NY Acad. Sci. 1019, 14.
  • Lennard A., Gorman P., Carrier M., Griffiths S., Scotney H., Sheer D. and Solari R. (1992) Cloning and chromosome mapping of the human interleukin-1 receptor antagonist gene. Cytokine 4, 8389.
  • Li X. and Qin J. (2005) Modulation of Toll-interleukin 1 receptor mediated signaling. Journal of molecular medicine (Berlin, Germany) 83, 258266.
  • Li Y., Liu L., Kang J., Sheng J. G., Barger S. W., Mrak R. E. and Griffin W. S. (2000) Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J. Neurosci. 20, 149155.
  • Li Y. J., Scott W. K., Zhang L. et al. (2006) Revealing the role of glutathione S-transferase omega in age-at-onset of Alzheimer and Parkinson diseases. Neurobiol. Aging 27, 10871093.
  • Licastro F., Veglia F., Chiappelli M., Grimaldi L. M. and Masliah E. (2004) A polymorphism of the interleukin-1 beta gene at position +3953 influences progression and neuro-pathological hallmarks of Alzheimer’s disease. Neurobiol. Aging 25, 10171022.
  • Lieberman A. P., Pitha P. M., Shin H. S. and Shin M. L. (1989) Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc. Natl Acad. Sci. USA 86, 63486352.
  • Lin L. L., Lin A. Y. and Knopf J. L. (1992) Cytosolic phospholipase A2 is coupled to hormonally regulated release of arachidonic acid. Proc. Natl Acad. Sci. USA 89, 61476151.
  • Lipton S. A. (1992) Memantine prevents HIV coat protein-induced neuronal injury in vitro. Neurology 42, 14031405.
  • Lipton S. A. and Rosenberg P. A. (1994) Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 330, 613622.
  • Liu T., McDonnell P. C., Young P. R., White R. F., Siren A. L., Hallenbeck J. M., Barone F. C. and Feurestein G. Z. (1993) Interleukin-1 beta mRNA expression in ischemic rat cortex. Stroke; J. Cerebral Circ. 24, 17461750.
  • Liu C., Chalmers D., Maki R. and De Souza E. B. (1996) Rat homolog of mouse interleukin-1 receptor accessory protein: cloning, localization and modulation studies. J. Neuroimmunol. 66, 4148.
  • Liu D., Xu G. Y., Pan E. and McAdoo D. J. (1999a) Neurotoxicity of glutamate at the concentration released upon spinal cord injury. Neuroscience 93, 13831389.
  • Liu X. H., Kwon D., Schielke G. P., Yang G. Y., Silverstein F. S. and Barks J. D. (1999b) Mice deficient in interleukin-1 converting enzyme are resistant to neonatal hypoxic-ischemic brain damage. J. Cereb. Blood Flow Metab. 19, 10991108.
  • Liu J. S., Zhao M. L., Brosnan C. F. and Lee S. C. (2001) Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am. J. Pathol. 158, 20572066.
  • Liu X. Y., Li C. Y., Bu H. et al. (2007) The Neuroprotective Potential of Phase II Enzyme Inducer on Motor Neuron Survival in Traumatic Spinal Cord Injury In vitro. Cell. Mol. Neurobiol. [Epub ahead of print]. doi: DOI: 10.1007/s10571-007-9219-0.
  • Loddick S. A. and Rothwell N. J. (1996) Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. J. Cereb. Blood Flow Metab. 16, 932940.
  • Loddick S. A., MacKenzie A. and Rothwell N. J. (1996) An ICE inhibitor, z-VAD-DCB attenuates ischaemic brain damage in the rat. Neuroreport 7, 14651468.
  • Loddick S. A., Wong M. L., Bongiorno P. B., Gold P. W., Licinio J. and Rothwell N. J. (1997) Endogenous interleukin-1 receptor antagonist is neuroprotective. Biochem. Biophys. Res. Commun. 234, 211215.
  • Loddick S. A., Liu C., Takao T., Hashimoto K. and De Souza E. B. (1998) Interleukin-1 receptors: cloning studies and role in central nervous system disorders. Brain Res. Brain Res. Rev. 26, 306319.
  • Lomedico P. T., Gubler U., Hellmann C. P., Dukovich M., Giri J. G., Pan Y. C., Collier K., Semionow R., Chua A. O. and Mizel S. B. (1984) Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature 312, 458462.
  • Longuemare M. C. and Swanson R. A. (1995) Excitatory amino acid release from astrocytes during energy failure by reversal of sodium-dependent uptake. J. Neurosci. Res. 40, 379386.
  • Lonnemann G., Endres S., Van der Meer J. W., Cannon J. G., Koch K. M. and Dinarello C. A. (1989) Differences in the synthesis and kinetics of release of interleukin 1 alpha, interleukin 1 beta and tumor necrosis factor from human mononuclear cells. Eur. J. Immunol. 19, 15311536.
  • Lotharius J., Dugan L. L. and O’Malley K. L. (1999) Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J. Neurosci. 19, 12841293.
  • Lovenberg T. W., Crowe P. D., Liu C., Chalmers D. T., Liu X. J., Liaw C., Clevenger W., Oltersdorf T., De Souza E. B. and Maki R. A. (1996) Cloning of a cDNA encoding a novel interleukin-1 receptor related protein (IL 1R-rp2). J. Neuroimmunol. 70, 113122.
  • Lowe J. S. and Leigh N. (2002) Disorders of Movement and System Neurodegenerations, in Greenfield’s neuropathology, 7th Edition, Vol. 2 (GrahamD. I. and LantosP. L. eds), pp 325430. Arnold (Hodder Headline Group), London, England.
  • Lu K. T., Wang Y. W., Yang J. T., Yang Y. L. and Chen H. I. (2005) Effect of interleukin-1 on traumatic brain injury-induced damage to hippocampal neurons. J. Neurotrauma 22, 885895.
  • Luheshi G., Hopkins S. J., Lefeuvre R. A., Dascombe M. J., Ghiara P. and Rothwell N. J. (1993) Importance of brain IL-1 type II receptors in fever and thermogenesis in the rat. Am. J. Pathol. 265, E585E591.
  • Lynch M. A. and Voss K. L. (1990) Arachidonic acid increases inositol phospholipid metabolism and glutamate release in synaptosomes prepared from hippocampal tissue. J. Neurochem. 55, 215221.
  • Lyras L., Cairns N. J., Jenner A., Jenner P. and Halliwell B. (1997) An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer’s disease. J. Neurochem. 68, 20612069.
  • Ma G., Chen S., Wang X., Ba M., Yang H. and Lu G. (2005) Short-term interleukin-1(beta) increases the release of secreted APP(alpha) via MEK1/2-dependent and JNK-dependent alpha-secretase cleavage in neuroglioma U251 cells. J. Neurosci. Res. 80, 683692.
  • MacKenzie A., Wilson H. L., Kiss-Toth E., Dower S. K., North R. A. and Surprenant A. (2001) Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity 15, 825835.
  • Maher J. and Hachinski V. (1993) Hypothermia as a potential treatment for cerebral ischemia. Cerebrovasc. Brain Metab. Rev. 5, 277300.
  • Maier J. A., Voulalas P., Roeder D. and Maciag T. (1990) Extension of the life-span of human endothelial cells by an interleukin-1 alpha antisense oligomer. Science (New York, NY) 249, 15701574.
  • Maimone D., Annunziata P., Simone I. L., Livrea P. and Guazzi G. C. (1993) Interleukin-6 levels in the cerebrospinal fluid and serum of patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J. Neuroimmunol. 47, 5561.
  • March C. J., Mosley B., Larsen A. et al. (1985) Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 315, 641647.
  • Marin P., Quignard J. F., Lafon-Cazal M. and Bockaert J. (1993) Non-classical glutamate receptors, blocked by both NMDA and non-NMDA antagonists, stimulate nitric oxide production in neurons. Neuropharmacology 32, 2936.
  • Marini H., Altavilla D., Bellomo M. et al. (2004) Modulation of IL-1 beta gene expression by lipid peroxidation inhibition after kainic acid-induced rat brain injury. Exp. Neurol. 188, 178186.
  • Martin M. U. and Falk W. (1997) The interleukin-1 receptor complex and interleukin-1 signal transduction. Eur. Cytokine Netw. 8, 517.
  • Martin M. U. and Wesche H. (2002) Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family. Biochim. Biophys. Acta 1592, 265280.
  • Martin D., Chinookoswong N. and Miller G. (1994) The interleukin-1 receptor antagonist (rhIL-1ra) protects against cerebral infarction in a rat model of hypoxia-ischemia. Exp. Neurol. 130, 362367.
  • Masaki T. (1989) The discovery, the present state, and the future prospects of endothelin. J. Cardiovasc. Pharmacol. 13(Suppl 5), S1S4.
  • Mattila K. M., Rinne J. O., Lehtimaki T., Roytta M., Ahonen J. P. and Hurme M. (2002) Association of an interleukin 1B gene polymorphism (-511) with Parkinson’s disease in Finnish patients. J. Med. Genet. 39, 400402.
  • Mattson M. P., Cheng B., Davis D., Bryant K., Lieberburg I. and Rydel R. E. (1992) beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 12, 376389.
  • Matute C., Alberdi E., Domercq M., Sanchez-Gomez M. V., Perez-Samartin A., Rodriguez-Antiguedad A. and Perez-Cerda F. (2007) Excitotoxic damage to white matter. J. Anat. 210, 693702.
  • McCann S. M., Licinio J., Wong M. L., Yu W. H., Karanth S. and Rettorri V. (1998) The nitric oxide hypothesis of aging. Exp. Gerontol. 33, 813826.
  • McFarland H. F. and Martin R. (2007) Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 8, 913919.
  • McGeer E. G. and McGeer P. L. (2005) Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis. BioDrugs 19, 3137.
  • McIntosh T. K. (1994) Neurochemical sequelae of traumatic brain injury: therapeutic implications. Cerebrovasc. Brain Metab. Rev. 6, 109162.
  • McIntosh T. K., Vink R., Soares H., Hayes R. and Simon R. (1989) Effects of the N-methyl-D-aspartate receptor blocker MK-801 on neurologic function after experimental brain injury. J. Neurotrauma 6, 247259.
  • Mecocci P., MacGarvey U. and Beal M. F. (1994) Oxidative damage to mitochondrial DNA is increased in Alzheimer’s disease. Ann. Neurol. 36, 747751.
  • Meister A. and Anderson M. E. (1983) Glutathione. Annu. Rev. Biochem. 52, 711760.
  • Meldrum B. and Garthwaite J. (1990) Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol. Sci. 11, 379387.
  • Miguel-Hidalgo J. J., Alvarez X. A., Cacabelos R. and Quack G. (2002) Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res. 958, 210221.
  • Miller B., Sarantis M., Traynelis S. F. and Attwell D. (1992) Potentiation of NMDA receptor currents by arachidonic acid. Nature 355, 722725.
  • Min K. J., Jou I. and Joe E. (2003) Plasminogen-induced IL-1beta and TNF-alpha production in microglia is regulated by reactive oxygen species. Biochem. Biophys. Res. Commun. 312, 969974.
  • Minami M., Kuraishi Y., Yabuuchi K., Yamazaki A. and Satoh M. (1992) Induction of interleukin-1 beta mRNA in rat brain after transient forebrain ischemia. J. Neurochem. 58, 390392.
  • Mirtella A., Tringali G., Guerriero G., Ghiara P., Parente L., Preziosi P. and Navarra P. (1995) Evidence that the interleukin-1 beta-induced prostaglandin E2 release from rat hypothalamus is mediated by type I and type II interleukin-1 receptors. J. Neuroimmunol. 61, 171177.
  • Mizushima H., Zhou C. J., Dohi K. et al. (2002) Reduced postischemic apoptosis in the hippocampus of mice deficient in interleukin-1. J. Comp. Neurol. 448, 203216.
  • Modi W. S., Masuda A., Yamada M., Oppenheim J. J., Matsushima K. and O’Brien S. J. (1988) Chromosomal localization of the human interleukin 1 alpha (IL-1 alpha) gene. Genomics 2, 310314.
  • Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M. and Nagatsu T. (1994) Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180, 147150.
  • Moldofsky H., Lue F. A., Eisen J., Keystone E. and Gorczynski R. M. (1986) The relationship of interleukin-1 and immune functions to sleep in humans. Psychosom. Med. 48, 309318.
  • Molenaar G. J., Berkenbosch F., Van Dam A. M. and Lugard C. M. (1993) Distribution of interleukin 1 beta immunoreactivity within the porcine hypothalamus. Brain Res. 608, 169174.
  • Montine T. J., Beal M. F., Robertson D., Cudkowicz M. E., Biaggioni I., O’Donnell H., Zackert W. E., Roberts L. J. and Morrow J. D. (1999) Cerebrospinal fluid F2-isoprostanes are elevated in Huntington’s disease. Neurology 52, 11041105.
  • Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H., Burnashev N., Sakmann B. and Seeburg P. H. (1992) Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science (New York, NY) 256, 12171221.
  • Morganti-Kossman M. C., Lenzlinger P. M., Hans V., Stahel P., Csuka E., Ammann E., Stocker R., Trentz O. and Kossmann T. (1997) Production of cytokines following brain injury: beneficial and deleterious for the damaged tissue. Mol. Psychiatry 2, 133136.
  • Moroni F., Attucci S., Cozzi A., Meli E., Picca R., Scheideler M. A., Pellicciari R., Noe C., Sarichelou I. and Pellegrini-Giampietro D. E. (2002) The novel and systemically active metabotropic glutamate 1 (mGlu1) receptor antagonist 3-MATIDA reduces post-ischemic neuronal death. Neuropharmacology 42, 741751.
  • Mrak R. E. and Griffin W. S. (2000) Interleukin-1 and the immunogenetics of Alzheimer disease. J. Neuropathol. Exp. Neurol. 59, 471476.
  • Mukhin A., Fan L. and Faden A. I. (1996) Activation of metabotropic glutamate receptor subtype mGluR1 contributes to post-traumatic neuronal injury. J. Neurosci. 16, 60126020.
  • Mulcahy N. J., Ross J., Rothwell N. J. and Loddick S. A. (2003) Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br. J. Pharmacol. 140, 471476.
  • Murphy S., Simmons M. L., Agullo L., Garcia A., Feinstein D. L., Galea E., Reis D. J., Minc-Golomb D. and Schwartz J. P. (1993) Synthesis of nitric oxide in CNS glial cells. Trends Neurosci. 16, 323328.
  • Murray C. A., Clements M. P. and Lynch M. A. (1999) Interleukin-1 induces lipid peroxidation and membrane changes in rat hippocampus: An age-related study. Gerontology 45, 136142.
  • Nakao N. and Brundin P. (1998) Neurodegeneration and glutamate induced oxidative stress. Prog. Brain Res. 116, 245263.
  • Nesic O., Xu G. Y., McAdoo D., High K. W., Hulsebosch C. and Perez-Pol R. (2001) IL-1 receptor antagonist prevents apoptosis and caspase-3 activation after spinal cord injury. J. Neurotrauma 18, 947956.
  • Nicholls D. and Attwell D. (1990) The release and uptake of excitatory amino acids. Trends Pharmacol. Sci. 11, 462468.
  • Nicklas W. J., Vyas I. and Heikkila R. E. (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36, 25032508.
  • Nicklin M. J., Barton J. L., Nguyen M., FitzGerald M. G., Duff G. W. and Kornman K. (2002) A sequence-based map of the nine genes of the human interleukin-1 cluster. Genomics 79, 718725.
  • Nicoll J. A., Mrak R. E., Graham D. I. et al. (2000) Association of interleukin-1 gene polymorphisms with Alzheimer’s disease. Ann. Neurol. 47, 365368.
  • Nieto-Sampedro M. and Berman M. A. (1987) Interleukin-1-like activity in rat brain: sources, targets, and effect of injury. J. Neurosci. Res. 17, 214219.
  • Nishimura M., Kuno S., Kaji R., Yasuno K. and Kawakami H. (2005) Glutathione-S-transferase-1 and interleukin-1beta gene polymorphisms in Japanese patients with Parkinson’s disease. Mov. Disord. 20, 901902.
  • Norris J. G., Tang L. P., Sparacio S. M. and Benveniste E. N. (1994) Signal transduction pathways mediating astrocyte IL-6 induction by IL-1 beta and tumor necrosis factor-alpha. J. Immunol. 152, 841850.
  • Nottet H. S. and Gendelman H. E. (1995) Unraveling the neuroimmune mechanisms for the HIV-1-associated cognitive/motor complex. Immunol. Today 16, 441448.
  • Nunomura A., Perry G., Aliev G. et al. (2001) Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60, 759767.
  • O’Banion M. K., Miller J. C., Chang J. W., Kaplan M. D. and Coleman P. D. (1996) Interleukin-1 beta induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures. J. Neurochem. 66, 25322540.
  • Obal Jr F. and Krueger J. M. (2003) Biochemical regulation of non-rapid-eye-movement sleep. Front. Biosci. 8, d520d550.
  • Ohtaki H., Funahashi H., Dohi K. et al. (2003) Suppression of oxidative neuronal damage after transient middle cerebral artery occlusion in mice lacking interleukin-1. Neurosci. Res. 45, 313324.
  • Ohtsuki T., Ruetzler C. A., Tasaki K. and Hallenbeck J. M. (1996) Interleukin-1 mediates induction of tolerance to global ischemia in gerbil hippocampal CA1 neurons. J. Cereb. Blood Flow Metab. 16, 11371142.
  • Okamura H., Tsutsi H., Komatsu T. et al. (1995) Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378, 8891.
  • Oleszak E. L., Zaczynska E., Bhattacharjee M., Butunoi C., Legido A. and Katsetos C. D. (1998) Inducible nitric oxide synthase and nitrotyrosine are found in monocytes/macrophages and/or astrocytes in acute, but not in chronic, multiple sclerosis. Clin. Diagn. Lab. Immunol. 5, 438445.
  • Ona V. O., Li M., Vonsattel J. P. et al. (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington’s disease. Nature 399, 263267.
  • Opp M. R. and Krueger J. M. (1991) Interleukin 1-receptor antagonist blocks interleukin 1-induced sleep and fever. Am. J. Physiol. 260, R453R457.
  • Opp M. R. and Krueger J. M. (1994a) Anti-interleukin-1 beta reduces sleep and sleep rebound after sleep deprivation in rats. Am. J. Physiol. 266, R688R695.
  • Opp M. R. and Krueger J. M. (1994b) Interleukin-1 is involved in responses to sleep deprivation in the rabbit. Brain Res. 639, 5765.
  • Orencole S. F. and Dinarello C. A. (1989) Characterization of a subclone (D10S) of the D10.G4.1 helper T-cell line which proliferates to attomolar concentrations of interleukin-1 in the absence of mitogens. Cytokine 1, 1422.
  • Owen A. D., Schapira A. H., Jenner P. and Marsden C. D. (1996) Oxidative stress and Parkinson’s disease. Ann. NY Acad. Sci. 786, 217223.
  • Panter S. S. and Faden A. I. (1992) Pretreatment with NMDA antagonists limits release of excitatory amino acids following traumatic brain injury. Neurosci. Lett. 136, 165168.
  • Panter S. S., Yum S. W. and Faden A. I. (1990) Alteration in extracellular amino acids after traumatic spinal cord injury. Ann. Neurol. 27, 9699.
  • Parker Jr W. D. and Swerdlow R. H. (1998) Mitochondrial dysfunction in idiopathic Parkinson disease. Am. J. Hum. Genet. 62, 758762.
  • Parnet P., Garka K. E., Bonnert T. P., Dower S. K. and Sims J. E. (1996) IL-1Rrp is a novel receptor-like molecule similar to the type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP. J. Biol. Chem. 271, 39673970.
  • Pasinelli P., Borchelt D. R., Houseweart M. K., Cleveland D. W. and Brown Jr R. H. (1998) Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase. Proc. Natl Acad. Sci. USA 95, 1576315768.
  • Patterson D., Jones C., Hart I., Bleskan J., Berger R., Geyer D., Eisenberg S. P., Smith Jr M. F. and Arend W. P. (1993) The human interleukin-1 receptor antagonist (IL1RN) gene is located in the chromosome 2q14 region. Genomics 15, 173176.
  • Pearson V. L., Rothwell N. J. and Toulmond S. (1999) Excitotoxic brain damage in the rat induces interleukin-1beta protein in microglia and astrocytes: correlation with the progression of cell death. Glia 25, 311323.
  • Perez-Severiano F., Rios C. and Segovia J. (2000) Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington’s disease. Brain Res. 862, 234237.
  • Perez-Severiano F., Santamaria A., Pedraza-Chaverri J., Medina-Campos O. N., Rios C. and Segovia J. (2004) Increased formation of reactive oxygen species, but no changes in glutathione peroxidase activity, in striata of mice transgenic for the Huntington’s disease mutation. Neurochem. Res. 29, 729733.
  • Perry T. L. and Yong V. W. (1986) Idiopathic Parkinson’s disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 67, 269274.
  • Phillis J. W., Ren J. and O’Regan M. H. (2000) Transporter reversal as a mechanism of glutamate release from the ischemic rat cerebral cortex: studies with DL-threo-beta-benzyloxyaspartate. Brain Res. 868, 105112.
  • Piani D. and Fontana A. (1994) Involvement of the cystine transport system xc- in the macrophage-induced glutamate-dependent cytotoxicity to neurons. J. Immunol. 152, 35783585.
  • Pinteaux E., Parker L. C., Rothwell N. J. and Luheshi G. N. (2002) Expression of interleukin-1 receptors and their role in interleukin-1 actions in murine microglial cells. J. Neurochem. 83, 754763.
  • Pioro E. P., Majors A. W., Mitsumoto H., Nelson D. R. and Ng T. C. (1999) 1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla. Neurology 53, 7179.
  • Pitt D., Werner P. and Raine C. S. (2000) Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 6, 6770.
  • Polidori M. C., Mecocci P., Browne S. E., Senin U. and Beal M. F. (1999) Oxidative damage to mitochondrial DNA in Huntington’s disease parietal cortex. Neurosci. Lett. 272, 5356.
  • Pratico D., Reiss P., Tang L. X., Sung S., Rokach J. and McIntosh T. K. (2002) Local and systemic increase in lipid peroxidation after moderate experimental traumatic brain injury. J. Neurochem. 80, 894898.
  • Pringle A. K., Niyadurupola N., Johns P., Anthony D. C. and Iannotti F. (2001) Interleukin-1beta exacerbates hypoxia-induced neuronal damage, but attenuates toxicity produced by simulated ischaemia and excitotoxicity in rat organotypic hippocampal slice cultures. Neurosci. Lett. 305, 2932.
  • Qin S., Colin C., Hinners I., Gervais A., Cheret C. and Mallat M. (2006) System Xc- and apolipoprotein E expressed by microglia have opposite effects on the neurotoxicity of amyloid-beta peptide 1-40. J. Neurosci. 26, 33453356.
  • Regan R. F. and Choi D. W. (1991) Glutamate neurotoxicity in spinal cord cell culture. Neuroscience 43, 585591.
  • Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S. and Mobius H. J. (2003) Memantine in moderate-to-severe Alzheimer’s disease. N. Engl. J. Med. 348, 13331341.
  • Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S. and Mobius H. J. (2006) A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch. Neurol. 63, 4954.
  • Relton J. K. and Rothwell N. J. (1992) Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res. Bull. 29, 243246.
  • Relton J. K., Martin D., Thompson R. C. and Russell D. A. (1996) Peripheral administration of Interleukin-1 Receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp. Neurol. 138, 206213.
  • Reynolds I. J. and Hastings T. G. (1995) Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation. J. Neurosci. 15, 33183327.
  • Ross F. M., Allan S. M., Rothwell N. J. and Verkhratsky A. (2003) A dual role for interleukin-1 in LTP in mouse hippocampal slices. J. Neuroimmunol. 144, 6167.
  • Rothenhausler H. B. (2006) [Clinical features, diagnosis and treatment of HIV-induced neuropsychiatric disorders]. Wiener medizinische Wochenschrift (1946) 156, 644656.
  • Rothstein J. D., Tsai G., Kuncl R. W., Clawson L., Cornblath D. R., Drachman D. B., Pestronk A., Stauch B. L. and Coyle J. T. (1990) Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann. Neurol. 28, 1825.
  • Rothstein J. D., Martin L. J. and Kuncl R. W. (1992) Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N. Engl. J. Med. 326, 14641468.
  • Rothstein J. D., Dykes-Hoberg M., Pardo C. A. et al. (1996) Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16, 675686.
  • Rothwell N. J. (1991) Functions and mechanisms of interleukin 1 in the brain. Trends Pharmacol. Sci. 12, 430436.
  • Rothwell N. J. (1999) Annual review prize lecture cytokines - killers in the brain? J. Physiol. 514, 317.
  • Rothwell N. J. and Luheshi G. N. (2000) Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci. 23, 618625.
  • Rothwell N. J. and Relton J. K. (1993) Involvement of interleukin-1 and lipocortin-1 in ischaemic brain damage. Cerebrovasc. Brain Metab. Rev. 5, 178198.
  • Rothwell N. J. and Strijbos P. J. (1995) Cytokines in neurodegeneration and repair. Int. J. Dev. Neurosci. 13, 179185.
  • Rothwell N., Allan S. and Toulmond S. (1997) The role of interleukin 1 in acute neurodegeneration and stroke: pathophysiological and therapeutic implications. J. Clin. Invest. 100, 26482652.
  • Rottkamp C. A., Atwood C. S., Joseph J. A., Nunomura A., Perry G. and Smith M. A. (2002) The state versus amyloid-beta: the trial of the most wanted criminal in Alzheimer disease. Peptides 23, 13331341.
  • Roux-Lombard P. (1998) The interleukin-1 family. Eur. Cytokine Netw. 9, 565576.
  • Rutledge E. M., Aschner M. and Kimelberg H. K. (1998) Pharmacological characterization of swelling-induced D-[3H]aspartate release from primary astrocyte cultures. Am. J. Physiol. 274, C1511C1520.
  • Sairanen T. R., Lindsberg P. J., Brenner M. and Siren A. L. (1997) Global forebrain ischemia results in differential cellular expression of interleukin-1beta (IL-1beta) and its receptor at mRNA and protein level. J. Cereb. Blood Flow Metab. 17, 11071120.
  • Sakakura Y., Sato H., Shiiya A., Tamba M., Sagara J., Matsuda M., Okamura N., Makino N. and Bannai S. (2007) Expression and function of cystine/glutamate transporter in neutrophils. J. Leukoc. Biol. 81, 974982.
  • Sasaki S., Komori T. and Iwata M. (2000) Excitatory amino acid transporter 1 and 2 immunoreactivity in the spinal cord in amyotrophic lateral sclerosis. Acta Neuropathol. 100, 138144.
  • Satta M. A., Jacobs R. A., Kaltsas G. A. and Grossman A. B. (1998) Endotoxin induces interleukin-1beta and nitric oxide synthase mRNA in rat hypothalamus and pituitary. Neuroendocrinology 67, 109116.
  • Schalkwijk C. G., Vervoordeldonk M., Pfeilschifter J. and Van Den Bosch H. (1993) Interleukin-1 beta-induced cytosolic phospholipase A2 activity and protein synthesis is blocked by dexamethasone in rat mesangial cells. FEBS Lett. 333, 339343.
  • Schielke G. P., Yang G. Y., Shivers B. D. and Betz A. L. (1998) Reduced ischemic brain injury in interleukin-1 beta converting enzyme-deficient mice. J. Cereb. Blood Flow Metab. 18, 180185.
  • Schmitz J., Owyang A., Oldham E. et al. (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23, 479490.
  • Schneider H., Pitossi F., Balschun D., Wagner A., Del Rey A. and Besedovsky H. O. (1998) A neuromodulatory role of interleukin-1beta in the hippocampus. Proc. Natl Acad. Sci. USA 95, 77787783.
  • Schulte T., Schols L., Muller T., Woitalla D., Berger K. and Kruger R. (2002) Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson’s disease. Neurosci. Lett. 326, 7072.
  • Seki Y., Feustel P. J., Keller Jr R. W., Tranmer B. I. and Kimelberg H. K. (1999) Inhibition of ischemia-induced glutamate release in rat striatum by dihydrokinate and an anion channel blocker. Stroke; J. Cerebral Circ. 30, 433440.
  • Serou M. J., DeCoster M. A. and Bazan N. G. (1999) Interleukin-1 beta activates expression of cyclooxygenase-2 and inducible nitric oxide synthase in primary hippocampal neuronal culture: platelet-activating factor as a preferential mediator of cyclooxygenase-2 expression. J. Neurosci. Res. 58, 593598.
  • Shaftel S. S., Carlson T. J., Olschowka J. A., Kyrkanides S., Matousek S. B. and O’Banion M. K. (2007a) Chronic interleukin-1beta expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood brain barrier permeability without overt neurodegeneration. J. Neurosci. 27, 93019309.
  • Shaftel S. S., Kyrkanides S., Olschowka J. A., Miller J. N., Johnson R. E. and O’Banion M. K. (2007b) Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J. Clin. Invest. 117, 15951604.
  • Shaw P. J., Chinnery R. M. and Ince P. G. (1994) [3H]D-aspartate binding sites in the normal human spinal cord and changes in motor neuron disease: a quantitative autoradiographic study. Brain Res. 655, 195201.
  • Shaw P. J., Forrest V., Ince P. G., Richardson J. P. and Wastell H. J. (1995) CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 4, 209216.
  • Sheng J. G., Mrak R. E. and Griffin W. S. (1995) Microglial interleukin-1 alpha expression in brain regions in Alzheimer’s disease: correlation with neuritic plaque distribution. Neuropathol. Appl. Neurobiol. 21, 290301.
  • Sheng J. G., Mrak R. E. and Griffin W. S. (1998a) Enlarged and phagocytic, but not primed, interleukin-1 alpha-immunoreactive microglia increase with age in normal human brain. Acta Neuropathol. 95, 229234.
  • Sheng J. G., Griffin W. S., Royston M. C. and Mrak R. E. (1998b) Distribution of interleukin-1-immunoreactive microglia in cerebral cortical layers: implications for neuritic plaque formation in Alzheimer’s disease. Neuropathol. Appl. Neurobiol. 24, 278283.
  • Shibayama M., Kuchiwaki H., Inao S., Yoshida K. and Ito M. (1996) Intercellular adhesion molecule-1 expression on glia following brain injury: participation of interleukin-1 beta. J. Neurotrauma 13, 801808.
  • Shiozaki T., Hayakata T., Tasaki O. et al. (2005) Cerebrospinal fluid concentrations of anti-inflammatory mediators in early-phase severe traumatic brain injury. Shock (Augusta, Ga 23, 406410.
  • Sian J., Dexter D. T., Lees A. J., Daniel S., Agid Y., Javoy-Agid F., Jenner P. and Marsden C. D. (1994) Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36, 348355.
  • Simpson D. M. and Tagliati M. (1994) Neurologic manifestations of HIV infection. Ann. Intern. Med. 121, 769785.
  • Sims J. E. and Dower S. K. (1994) Interleukin-1 receptors. Eur. Cytokine Netw. 5, 539546.
  • Sims J. E., Gayle M. A., Slack J. L. et al. (1993) Interleukin 1 signaling occurs exclusively via the type I receptor. Proc. Natl Acad. Sci. USA 90, 61556159.
  • Singer I. I., Scott S., Chin J., Bayne E. K., Limjuco G., Weidner J., Miller D. K., Chapman K. and Kostura M. J. (1995) The interleukin-1 beta-converting enzyme (ICE) is localized on the external cell surface membranes and in the cytoplasmic ground substance of human monocytes by immuno-electron microscopy. J. Exp. Med. 182, 14471459.
  • Skifter D. A., Allegrini P. R., Wiessner C. and Mir A. K. (2002) Similar time-course of interleukin-1 beta production and extracellular-signal-regulated kinase (ERK) activation in permanent focal brain ischemic injury. Metab. Brain Dis. 17, 131138.
  • Small D. H. (2004) Do acetylcholinesterase inhibitors boost synaptic scaling in Alzheimer’s disease? Trends Neurosci. 27, 245249.
  • Smith S. L., Andrus P. K., Zhang J. R. and Hall E. D. (1994) Direct measurement of hydroxyl radicals, lipid peroxidation, and blood-brain barrier disruption following unilateral cortical impact head injury in the rat. J. Neurotrauma 11, 393404.
  • Smith M. A., Perry G., Richey P. L., Sayre L. M., Anderson V. E., Beal M. F. and Kowall N. (1996) Oxidative damage in Alzheimer’s. Nature 382, 120121.
  • Smith M. A., Nunomura A., Zhu X., Takeda A. and Perry G. (2000a) Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease. Antioxid. Redox Signal. 2, 413420.
  • Smith T., Groom A., Zhu B. and Turski L. (2000b) Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. 6, 6266.
  • Smith M. A., Casadesus G., Joseph J. A. and Perry G. (2002) Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic. Biol. Med. 33, 11941199.
  • Sonsalla P. K., Nicklas W. J. and Heikkila R. E. (1989) Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science (New York, NY) 243, 398400.
  • Sonsalla P. K., Riordan D. E. and Heikkila R. E. (1991) Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice. J. Pharmacol. Exp. Ther. 256, 506512.
  • Sonsalla P. K., Albers D. S. and Zeevalk G. D. (1998) Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism. Amino acids 14, 6974.
  • Srivastava R., Brouillet E., Beal M. F., Storey E. and Hyman B. T. (1993) Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment: a stereological estimate of neuronal loss. Neurobiol. Aging 14, 295301.
  • Steiner J., Haughey N., Li W., Venkatesan A., Anderson C., Reid R., Malpica T., Pocernich C., Butterfield D. A. and Nath A. (2006) Oxidative stress and therapeutic approaches in HIV dementia. Antioxid. Redox Signal. 8, 20892100.
  • Steinkasserer A., Spurr N. K., Cox S., Jeggo P. and Sim R. B. (1992) The human IL-1 receptor antagonist gene (IL1RN) maps to chromosome 2q14-q21, in the region of the IL-1 alpha and IL-1 beta loci. Genomics 13, 654657.
  • Stella N., Estelles A., Siciliano J., Tence M., Desagher S., Piomelli D., Glowinski J. and Premont J. (1997) Interleukin-1 enhances the ATP-evoked release of arachidonic acid from mouse astrocytes. J. Neurosci. 17, 29392946.
  • Storey E., Hyman B. T., Jenkins B., Brouillet E., Miller J. M., Rosen B. R. and Beal M. F. (1992) 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J. Neurochem. 58, 19751978.
  • Stover J. F., Pleines U. E., Morganti-Kossmann M. C., Kossmann T., Lowitzsch K. and Kempski O. S. (1997) Neurotransmitters in cerebrospinal fluid reflect pathological activity. Eur. J. Clin. Invest. 27, 10381043.
  • Strijbos P. J. and Rothwell N. J. (1995) Interleukin-1 beta attenuates excitatory amino acid-induced neurodegeneration in vitro: involvement of nerve growth factor. J. Neurosci. 15, 34683474.
  • Stroemer R. P. and Rothwell N. J. (1998) Exacerbation of ischemic brain damage by localized striatal injection of interleukin-1beta in the rat. J. Cereb. Blood Flow Metab. 18, 833839.
  • Sung C. S., Wen Z. H., Chang W. K., Ho S. T., Tsai S. K., Chang Y. C. and Wong C. S. (2004) Intrathecal interleukin-1beta administration induces thermal hyperalgesia by activating inducible nitric oxide synthase expression in the rat spinal cord. Brain Res. 1015, 145153.
  • Szatkowski M. and Attwell D. (1994) Triggering and execution of neuronal death in brain ischaemia: two phases of glutamate release by different mechanisms. Trends Neurosci. 17, 359365.
  • Szatkowski M., Barbour B. and Attwell D. (1990) Non-vesicular release of glutamate from glial cells by reversed electrogenic glutamate uptake. Nature 348, 443446.
  • Taishi P., Bredow S., Guha-Thakurta N., Obal Jr F. and Krueger J. M. (1997) Diurnal variations of interleukin-1 beta mRNA and beta-actin mRNA in rat brain. J. Neuroimmunol. 75, 6974.
  • Takahashi J. L., Giuliani F., Power C., Imai Y. and Yong V. W. (2003) Interleukin-1beta promotes oligodendrocyte death through glutamate excitotoxicity. Ann. Neurol. 53, 588595.
  • Takao T., Tracey D. E., Mitchell W. M. and De Souza E. B. (1990) Interleukin-1 receptors in mouse brain: characterization and neuronal localization. Endocrinology 127, 30703078.
  • Tarkowski E., Rosengren L., Blomstrand C., Jensen C., Ekholm S. and Tarkowski A. (1999) Intrathecal expression of proteins regulating apoptosis in acute stroke. Stroke; J. Cerebral Circ. 30, 321327.
  • Taupin V., Toulmond S., Serrano A., Benavides J. and Zavala F. (1993) Increase in IL-6, IL-1 and TNF levels in rat brain following traumatic lesion. Influence of pre- and post-traumatic treatment with Ro5 4864, a peripheral-type (p site) benzodiazepine ligand. J. Neuroimmunol. 42, 177185.
  • Taylor S. L., Renshaw B. R., Garka K. E., Smith D. E. and Sims J. E. (2002) Genomic organization of the interleukin-1 locus. Genomics 79, 726733.
  • Tehranian R., Andell-Jonsson S., Beni S. M., Yatsiv I., Shohami E., Bartfai T., Lundkvist J. and Iverfeldt K. (2002) Improved recovery and delayed cytokine induction after closed head injury in mice with central overexpression of the secreted isoform of the interleukin-1 receptor antagonist. J. Neurotrauma 19, 939951.
  • Terry Jr A. V. and Buccafusco J. J. (2003) The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J. Pharmacol. Exp. Ther. 306, 821827.
  • Thornberry N. A., Bull H. G., Calaycay J. R. et al. (1992) A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 356, 768774.
  • Thornton P., Pinteaux E., Gibson R. M., Allan S. M. and Rothwell N. J. (2006) Interleukin-1-induced neurotoxicity is mediated by glia and requires caspase activation and free radical release. J. Neurochem. 98, 258266.
  • Tipton K. F. and Singer T. P. (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J. Neurochem. 61, 11911206.
  • Toggas S. M., Masliah E. and Mucke L. (1996) Prevention of HIV-1 gp120-induced neuronal damage in the central nervous system of transgenic mice by the NMDA receptor antagonist memantine. Brain Res. 706, 303307.
  • Tomozawa Y., Inoue T. and Satoh M. (1995) Expression of type I interleukin-1 receptor mRNA and its regulation in cultured astrocytes. Neurosci. Lett. 195, 5760.
  • Tong L., Balazs R., Soiampornkul R., Thangnipon W. and Cotman C. W. (2008) Interleukin-1[beta] impairs brain derived neurotrophic factor-induced signal transduction. Neurobiol. Aging [Epub ahead of print]. doi: DOI: 10.1016/j.neurobiolaging.2007.02.027.
  • Torigoe K., Ushio S., Okura T. et al. (1997) Purification and characterization of the human interleukin-18 receptor. J. Biol. Chem. 272, 2573725742.
  • Toulmond S. and Rothwell N. J. (1995) Interleukin-1 receptor antagonist inhibits neuronal damage caused by fluid percussion injury in the rat. Brain Res. 671, 261266.
  • Touzani O., Boutin H., LeFeuvre R., Parker L., Miller A., Luheshi G. and Rothwell N. (2002) Interleukin-1 influences ischemic brain damage in the mouse independently of the interleukin-1 type I receptor. J. Neurosci. 22, 3843.
  • Towne J. E., Garka K. E., Renshaw B. R., Virca G. D. and Sims J. E. (2004) Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J. Biol. Chem. 279, 1367713688.
  • Toyooka K., Watanabe Y., Iritani S. et al. (2003) A decrease in interleukin-1 receptor antagonist expression in the prefrontal cortex of schizophrenic patients. Neurosci. Res. 46, 299307.
  • Troy C. M., Stefanis L., Prochiantz A., Greene L. A. and Shelanski M. L. (1996) The contrasting roles of ICE family proteases and interleukin-1beta in apoptosis induced by trophic factor withdrawal and by copper/zinc superoxide dismutase down-regulation. Proc. Natl Acad. Sci. USA 93, 56355640.
  • Tunez I., Montilla P., Del Carmen Munoz M., Feijoo M. and Salcedo M. (2004) Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington’s disease. J. Pineal Res. 37, 252256.
  • Turski L., Bressler K., Rettig K. J., Loschmann P. A. and Wachtel H. (1991) Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349, 414418.
  • Uehara A., Gottschall P. E., Dahl R. R. and Arimura A. (1987) Stimulation of ACTH release by human interleukin-1 beta, but not by interleukin-1 alpha, in conscious, freely-moving rats. Biochem. Biophys. Res. Commun. 146, 12861290.
  • Van Damme P., Dewil M., Robberecht W. and Van Den Bosch L. (2005) Excitotoxicity and amyotrophic lateral sclerosis. Neuro-degenerative diseases 2, 147159.
  • Vandenabeele P. and Fiers W. (1991) Is amyloidogenesis during Alzheimer’s disease due to an IL-1-/IL-6-mediated ‘acute phase response’ in the brain? Immunol. Today 12, 217219.
  • Vazquez E., Herrero I., Miras-Portugal M. T. and Sanchez-Prieto J. (1994) Role of arachidonic acid in the facilitation of glutamate release from rat cerebrocortical synaptosomes independent of metabotropic glutamate receptor responses. Neurosci. Lett. 174, 913.
  • Vidwans A. S. and Hewett S. J. (2004) Enhanced release of synaptic glutamate underlies the potentiation of oxygen-glucose deprivation-induced neuronal injury after induction of NOS-2. Exp. Neurol. 190, 91101.
  • Viviani B., Corsini E., Binaglia M., Galli C. L. and Marinovich M. (2001) Reactive oxygen species generated by glia are responsible for neuron death induced by human immunodeficiency virus-glycoprotein 120 in vitro. Neuroscience 107, 5158.
  • Viviani B., Bartesaghi S., Gardoni F. et al. (2003) Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J. Neurosci. 23, 86928700.
  • Viviani B., Gardoni F., Bartesaghi S., Corsini E., Facchi A., Galli C. L., Di Luca M. and Marinovich M. (2006) Interleukin-1 beta released by gp120 drives neural death through tyrosine phosphorylation and trafficking of NMDA receptors. J. Biol. Chem. 281, 3021230222.
  • Wahl F., Obrenovitch T. P., Hardy A. M., Plotkine M., Boulu R. and Symon L. (1994) Extracellular glutamate during focal cerebral ischaemia in rats: time course and calcium dependency. J. Neurochem. 63, 10031011.
  • Wahner A. D., Sinsheimer J. S., Bronstein J. M. and Ritz B. (2007) Inflammatory cytokine gene polymorphisms and increased risk of Parkinson disease. Arch. Neurol. 64, 836840.
  • Wakabayashi G., Gelfand J. A., Burke J. F., Thompson R. C. and Dinarello C. A. (1991) A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J. 5, 338343.
  • Walker D. G., Kim S. U. and McGeer P. L. (1995) Complement and cytokine gene expression in cultured microglial derived from postmortem human brains. J. Neurosci. Res. 40, 478493.
  • Wallstrom E., Diener P., Ljungdahl A., Khademi M., Nilsson C. G. and Olsson T. (1996) Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis. J. Neurol. Sci. 137, 8996.
  • Wang C. X., Olschowka J. A. and Wrathall J. R. (1997a) Increase of interleukin-1beta mRNA and protein in the spinal cord following experimental traumatic injury in the rat. Brain Res. 759, 190196.
  • Wang X., Barone F. C., Aiyar N. V. and Feuerstein G. Z. (1997b) Interleukin-1 receptor and receptor antagonist gene expression after focal stroke in rats. Stroke; J. Cerebral Circ. 28, 155161.
  • Wang X., Li X., Currie R. W., Willette R. N., Barone F. C. and Feuerstein G. Z. (2000) Application of real-time polymerase chain reaction to quantitate induced expression of interleukin-1beta mRNA in ischemic brain tolerance. J. Neurosci. Res. 59, 238246.
  • Wang X. F., Yin L., Hu J. G., Huang L. D., Yu P. P., Jiang X. Y., Xu X. M. and Lu P. H. (2006) Expression and localization of p80 interleukin-1 receptor protein in the rat spinal cord. J. Mol. Neurosci. 29, 4553.
  • Watt J. A. and Hobbs N. K. (2000) Interleukin-1beta immunoreactivity in identified neurons of the rat magnocellular neurosecretory system: evidence for activity-dependent release. J. Neurosci. Res. 60, 478489.
  • Webb A. C., Collins K. L., Auron P. E., Eddy R. L., Nakai H., Byers M. G., Haley L. L., Henry W. M. and Shows T. B. (1986) Interleukin-1 gene (IL1) assigned to long arm of human chromosome 2. Lymphokine Res. 5, 7785.
  • Wellington C. L., Ellerby L. M., Hackam A. S. et al. (1998) Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 273, 91589167.
  • Werner P., Pitt D. and Raine C. S. (2000) Glutamate excitotoxicity--a mechanism for axonal damage and oligodendrocyte death in Multiple Sclerosis? J. Neural Transm. 60, 375385.
  • Wesche H., Korherr C., Kracht M., Falk W., Resch K. and Martin M. U. (1997) The interleukin-1 receptor accessory protein (IL-1RAcP) is essential for IL-1-induced activation of interleukin-1 receptor-associated kinase (IRAK) and stress-activated protein kinases (SAP kinases). J. Biol. Chem. 272, 77277731.
  • Wong M. L. and Licinio J. (1994) Localization of interleukin 1 type I receptor mRNA in rat brain. Neuroimmunomodulation 1, 110115.
  • Woodroofe M. N., Sarna G. S., Wadhwa M., Hayes G. M., Loughlin A. J., Tinker A. and Cuzner M. L. (1991) Detection of interleukin-1 and interleukin-6 in adult rat brain, following mechanical injury, by in vivo microdialysis: evidence of a role for microglia in cytokine production. J. Neuroimmunol. 33, 227236.
  • Wu D. C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D. K., Ischiropoulos H. and Przedborski S. (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22, 17631771.
  • Xu G. Y., Hughes M. G., Zhang L., Cain L. and McAdoo D. J. (2005) Administration of glutamate into the spinal cord at extracellular concentrations reached post-injury causes functional impairments. Neurosci. Lett. 384, 271276.
  • Xue S., Brockman D. E., Slater D. M. and Myatt L. (1995) Interleukin-1 beta induces the synthesis and activity of cytosolic phospholipase A2 and the release of prostaglandin E2 in human amnion-derived WISH cells. Prostaglandins 49, 351369.
  • Yabuuchi K., Minami M., Katsumata S., Yamazaki A. and Satoh M. (1994) An in situ hybridization study on interleukin-1 beta mRNA induced by transient forebrain ischemia in the rat brain. Brain Res. 26, 135142.
  • Yamasaki Y., Matsuura N., Shozuhara H., Onodera H., Itoyama Y. and Kogure K. (1995) Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke; J. Cerebral Circ. 26, 676680.
  • Yanase M., Sakou T. and Fukuda T. (1995) Role of N-methyl-D-aspartate receptor in acute spinal cord injury. J. Neurosurg. 83, 884888.
  • Yang G. Y., Zhao Y. J., Davidson B. L. and Betz A. L. (1997) Overexpression of interleukin-1 receptor antagonist in the mouse brain reduces ischemic brain injury. Brain Res. 751, 181188.
  • Yang G. Y., Liu X. H., Kadoya C., Zhao Y. J., Mao Y., Davidson B. L. and Betz A. L. (1998a) Attenuation of ischemic inflammatory response in mouse brain using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist. J. Cereb. Blood Flow Metab. 18, 840847.
  • Yang Y., Quitschke W. W. and Brewer G. J. (1998b) Upregulation of amyloid precursor protein gene promoter in rat primary hippocampal neurons by phorbol ester, IL-1 and retinoic acid, but not by reactive oxygen species. Brain Res. 60, 4049.
  • Yang G. Y., Mao Y., Zhou L. F., Gong C., Ge H. L. and Betz A. L. (1999a) Expression of intercellular adhesion molecule 1 (ICAM-1) is reduced in permanent focal cerebral ischemic mouse brain using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist. Brain Res. 65, 143150.
  • Yang G. Y., Mao Y., Zhou L. F., Ye W., Liu X. H., Gong C. and Lorris Betz A. (1999b) Attenuation of temporary focal cerebral ischemic injury in the mouse following transfection with interleukin-1 receptor antagonist. Brain Res. 72, 129137.
  • Yang L., Blumbergs P. C., Jones N. R., Manavis J., Sarvestani G. T. and Ghabriel M. N. (2004) Early expression and cellular localization of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in human traumatic spinal cord injury. Spine 29, 966971.
  • Yang L., Jones N. R., Blumbergs P. C., Van Den Heuvel C., Moore E. J., Manavis J., Sarvestani G. T. and Ghabriel M. N. (2005) Severity-dependent expression of pro-inflammatory cytokines in traumatic spinal cord injury in the rat. J Clin Neurosci 12, 276284.
  • Yao J., Keri J. E., Taffs R. E. and Colton C. A. (1992) Characterization of interleukin-1 production by microglia in culture. Brain Res. 591, 8893.
  • Ye Z. C. and Sontheimer H. (1999) Glioma cells release excitotoxic concentrations of glutamate. Cancer Res. 59, 43834391.
  • Ye Z. C., Wyeth M. S., Baltan-Tekkok S. and Ransom B. R. (2003) Functional hemichannels in astrocytes: a novel mechanism of glutamate release. J. Neurosci. 23, 35883596.
  • Young P. R. and Sylvester D. (1989) Cloning of rabbit interleukin-1 beta: differential evolution of IL-1 alpha and IL-1 beta proteins. Protein Eng. 2, 545551.
  • Yu A. C., Chan P. H. and Fishman R. A. (1987) Arachidonic acid inhibits uptake of glutamate and glutamine but not of GABA in cultured cerebellar granule cells. J. Neurosci. Res. 17, 424427.
  • Zetterstrom M., Lundkvist J., Malinowsky D., Eriksson G. and Bartfai T. (1998) Interleukin-1-mediated febrile responses in mice and interleukin-1 beta activation of NFkappaB in mouse primary astrocytes, involves the interleukin-1 receptor accessory protein. Eur. Cytokine Netw. 9, 131138.
  • Zhang Z., Chopp M., Goussev A. and Powers C. (1998) Cerebral vessels express interleukin 1beta after focal cerebral ischemia. Brain Res. 784, 210217.
  • Zhang W., Smith C., Howlett C. and Stanimirovic D. (2000) Inflammatory activation of human brain endothelial cells by hypoxic astrocytes in vitro is mediated by IL-1beta. J. Cereb. Blood Flow Metab. 20, 967978.
  • Zhao M. L., Kim M. O., Morgello S. and Lee S. C. (2001) Expression of inducible nitric oxide synthase, interleukin-1 and caspase-1 in HIV-1 encephalitis. J. Neuroimmunol. 115, 182191.
  • Zhu T., Yao Z., Yuan H. N., Lu B. G. and Yang S. Y. (2004) Changes of interleukin-1 beta, tumor necrosis factor alpha and interleukin-6 in brain and plasma after brain injury in rats. Chin. J. Traumatol. = Zhonghua chuang shang za zhi/Chin. Med. Assoc. 7, 3235.
  • Zhu X., Su B., Wang X., Smith M. A. and Perry G. (2007) Causes of oxidative stress in Alzheimer disease. Cell Mol. Life Sci. 64, 22022210.